

Pharmacokinetic analysis of targeted nanonubbles for quantitative assessment of PSMA expression in prostate cancer

Citation for published version (APA):

Turco, S., Perera, R. A., Wijkstra, H., Exner, A. A., & Mischi, M. (2019). *Pharmacokinetic analysis of targeted nanonubbles for quantitative assessment of PSMA expression in prostate cancer*. Abstract from 24th European Symposium on Contrast Ultrasound Imaging, January 17-18, 2019, Rotterdam, The Netherlands, Rotterdam, Netherlands.

Document status and date:

Published: 01/01/2019

Document Version:

Publisher's PDF, also known as Version of Record (includes final page, issue and volume numbers)

Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

www.tue.nl/taverne

Take down policy

If you believe that this document breaches copyright please contact us at:

openaccess@tue.nl

providing details and we will investigate your claim.



Pharmacokinetic analysis of targeted nanobubbles for quantitative assessment of PSMA expression in prostate cancer

Simona Turco¹, Reshani Perera²,

Hessel Wijkstra^{1,3}, Agata A. Exner², M. Mischi¹

¹Biomedical diagnostics lab, Eindhoven University of Technology, Eindhoven, the Netherlands

²Department of Radiology, Case Western Reserve University, Cleveland OH, United States

³Department of Urology, Amsterdam University Medical Center, Amsterdam, the Netherlands

Background

- Despite showing promise, contrast enhanced ultrasound (CEUS) has yet not reached sufficient sensitivity for prostate cancer diagnosis [1]
- Molecular imaging by microbubbles (MBs) targeted to the vascular endothelial growth factor receptor 2 is promising, but the detection rate for prostate cancer in a phase-0 clinical trial was limited to 65% [2]
- Ultrasound nanobubbles (NBs) are emerging for targeted imaging and therapy. Being able to cross the vascular endothelium, NBs permit including targets beyond the vessel wall. A long-circulating NB targeted to the prostate-specific membrane antigen (PSMA) was recently developed, showing promise for selective accumulation in tumors expressing PSMA, such as prostate cancer [3].
- In this work, we propose pharmacokinetic modeling of the kinetics of PSMA-targeted NBs by the simplified reference tissue model [4] for quantitative assessment of NB binding.

Methods


Pharmacokinetic modeling

The kinetics of PSMA-targeted NBs can be described by a 3-compartment model: the plasma compartment, the “free” tissue compartment, and the “bound” tissue compartment. When a reference tissue is available, the acoustic intensity in a pixel can be described by the **simplified reference tissue model** [4] as

$$I_t(t) = R_1 I_r(t) + \left(k_2 - \frac{R_1 k_2}{1 + BP} \right) I_r(t) * e^{-\frac{k_2}{1+BP}t}$$

- **BP**, binding potential
- $I_t(t)$, linearized acoustic intensity in the target tissue
- $I_r(t)$, linearized acoustic intensity in the reference tissue
- k_2 , transfer rate from free to plasma compartment
- R_1 , ratio of transfer rate from plasma to target tissue over transfer rate from plasma to reference tissue

Dual-tumor mouse model



Subcutaneous implantation of


- PSMA-positive PC3pip cells in one flank,
- PSMA-negative PC3flu cells in the other flank.

Ultrasound acquisition


- Toshiba AplioXG (Toshiba Medical System, Japan) with PLT-1204BT probe working at 12 MHz (MI, 0.1; dynamic range, 65dB; gain, 70dB; imaging frame rate, 0.2 frames/s).
- Injection of 200- μ L bolus of either **non-targeted NBs** or **PSMA-targeted NBs**.
- Repeated high-intensity flashes followed by injection of 200- μ L bolus of **Lumason** (Bracco Diagnostics Inc, Switzerland).

Results

Lumason



Non-targeted NBs



PSMA-targeted NBs




Fig. 1 Examples of TICs extracted from the reference tissue (PSMA-negative ROI) and target tissue (PSMA-positive ROI), together with corresponding model fit of the target TIC.




Fig. 2 Estimated BP for Lumason, non-targeted NB, and PSMA-targeted NB in a PSMA-positive tumor. The PSMA-negative is used as reference tissue.

Conclusions

The estimated BP was nearly zero for conventional MBs, while the highest BP was obtained for PSMA-targeted NBs, suggesting that these NBs are able to reach and bind to the target. The non-zero BP value obtained for non-targeted NBs may be due to the fact the BP reflects both binding and unbinding. To conclude, pharmacokinetic analysis of the kinetics of PSMA-targeted NBs by the simplified reference tissue model is feasible. The binding potential BP may represent a promising parameter for quantitative assessment of PSMA expression in prostate tumors. In the future, alternative pharmacokinetic models not requiring the presence of a reference tissue in the field of view will be investigated.

References

- [1] Wink, M., et al., European Urology 54.5 (2008): 982-993
- [2] Smeenge, M, et al., Investigative Radiology 52.7 (2017): 419-427
- [3] Perera, R. H., et al, IEEE International Ultrasonic Symposium 2018, Kobe, Japan
- [4] Lammertsma, A. A, Neuroimage 4.3 (1996): 153-158

Lumason
Non-targeted NBs
PSMA-targeted NBs